Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both

Current Opinion in Organ Transplantation

Volumn 14, Issue 4, 2009, Pages 410-413

  Doxiadis, Ilias I N ^a   Claas, Frans H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acceptable mismatch program; Eurotransplant; Highly sensitized patient; Kidney transplantation

Indexed keywords

BORTEZOMIB; CD20 ANTIBODY; IMMUNOGLOBULIN; RITUXIMAB;

DESENSITIZATION; GRAFT SURVIVAL; HEALTH PROGRAM; HUMAN; KIDNEY TRANSPLANTATION; REVIEW;

ANTIBODIES; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ORGAN TRANSPLANTATION; PATIENT SELECTION; RISK ASSESSMENT; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 68849123872     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832c433f     Document Type: Review

References (27)

1. Gebel HM, Bray RA, Nickerson P. Pretransplant assessment of donorreactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003; 3:1488-1500. (Pubitemid 37541506)
2. Patel R, Terasaki PI. Significance of the positive crossmatch in kidney transplantation. N Eng J Med 1969; 280:735-739.
3. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted in crossmatch- positive recipients. Transplantation 2000; 70:887-895.
4. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower sensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15:3256-3262. (Pubitemid 39578859)
5. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Eng J Med 2008; 359:242-251. Introduction of a new desensitization protocol to help highly sensitized patient to a graft. (Pubitemid 352008439)
6. Van Rood JJ. A proposal for international cooperation in organ transplantation; Eurotransplant. In: Curtoni nES, Mattiuz PL, Tosi RM, editors. Histocompatibility Testing 1967 Munksgaard, Copenhagen, Denmark 1967. pp. 451-453.
7. De Meester J, Persijn GG, Wujciak T, et al. The new Eurotransplant kidney allocation system: report one year after implementation. Transplantation 1998; 66:1154-1159. (Pubitemid 28530317)
8. Claas FHJ, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft survival. Transplantation 2004; 78:190-193.
9. Doxiadis IIN, Witvliet M, Verduyn W, et al. The relevance of proficiency testing for Laboratories involved in cadaveric transplantation and its consequences for graft survival. Clin Transpl 2000; 99-103.
10. Doxiadis II, Duquesnoy RJ, Claas FH. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol 2005; 5:536-540.
11. Zoet YM, Eijsink C, Kardol MJ, et al. The single antigen expressing lines (SALs) concept: an excellent tool for screening for HLA-specific antibodies. Hum Immunol 2005; 66:519-525. (Pubitemid 40797550)
12. Morales-Buenrostro LE, Terasaki PI, Marino-Vasquez LA, et al. 'Natural' human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86:1111-1115. Caution in the interpretation of HLA screening results with respect to transplantation irrelevant antibodies.
13. Duquesnoy RJ. Clinical usefulness of HLAMatchmaker in HLA epitope matching for organ transplantation. Cur Opin Immunol 2008; 20:594-601.
14. Duquesnoy RJ, Witvliet M, Doxiadis IIN, et al. HLAMatchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates. Transpl Int 2004; 17:22-30. (Pubitemid 38197023)
15. Jackson AM, Zachary AA. The problem of transplanting the sensitized patients: whose problem is it? Front Biosci 2008; 13:1396-1412.
16. Fuggle SV, Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 2008; 86:384-390.
17. Bray RA, Nickerson PW, Kerman RH, et al. Evolution of HLA antibody detection: technology emulating biology. Immunol Res 2004; 29:41-54.
18. Vaidya S, Partlow D, Susskind B, et al. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation 2006; 82:1524-1528. (Pubitemid 44967637)
19. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen specific antibodies. Hum Immunol 2008; 69:591-604.
20. Van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85:1086-1090. Report on the relevance of Luminex-only defined antibodies.
21. Claas FHJ. HLA antibody testing: a tool to facilitate not to prevent organ transplantation. Int J Immunogenet 2008; 35:275-277.
22. De Klerk M, Witvliet MD, Haase-Kromwijk BJ, et al. Hurdles, barriers, and successes of a national living donor kidney exchange program. Transplantation 2008; 86:1749-1753.
23. Segev DL, Kucirka LM, Gentry SE, Montgomery RA. Utilization and outcome of kidney paired donation in the United States. Transplantation 2008; 86:502-510.
24. Munoz AS, Rioveros AA, Cabanayan-Casasola CB, et al. Rituximab in highly sensitized kidney transplant patients. Transplant Proc 2008; 40:2218-2221.
25. Jordan SC, Peng A, Vo AA. Therapeutic strategies in management of the highly HLA-sensitized and ABO incompatible transplant recipients. Contrib Nephrol 2009; 162:13-26.
26. Everly MJ, Everly JJ, Susskind, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86:1754. The use of bortezomib opens news ways in antibody 'removal' treatment.
27. Everly MJ, Everly JJ, Susskind, et al. Proteasome inhibition reduces donor specific antibody levels. Transplant Proc 2009; 41:105-107.